Optimising Cancer Immunotherapy: Challenges and Opportunities

Chairpeople:

Alexander M. M. Eggermont,³ Ignacio Melero⁴

Speakers:

Joachim G. Aerts,⁵ Mario Colombo,⁶ George Coukos,⁷ Eric Deutsch,³ Thomas Powles⁸

Authors: Tristin Abair,¹ Robert E. Coleman²
Panel Members: Jürgen Becker,⁹ Christian Blank,¹⁰ Rolf Kiessling,¹¹ Michele Maio,¹² Martin Schuler¹³

1. prIME Oncology, Atlanta, Georgia, USA
2. prIME Oncology, The Hague, Netherlands; University of Sheffield, Weston Park Hospital, Sheffield, UK
3. Gustave Roussy, Villejuif, France
4. Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
5. Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
6. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7. Ludwig Center for Cancer Research, Lausanne, France
8. Barts Cancer Institute, Queen Mary University of London, London, UK
9. German Cancer Research Forum (DKTK), Medical University of Essen, Essen, Germany
10. Netherlands Cancer Institute, Amsterdam, Netherlands
11. Karolinska Institutet, Stockholm, Sweden
12. University of Siena, Siena, Italy
13. Universität Duisburg-Essen, Essen, Germany

Disclosure:

Dr Abair has no relevant financial relationships to disclose. Dr Coleman has received research funding to his institution from Bayer and Amgen. Dr Eggermont has received consulting fees from Actelion, Bristol-Myers Squibb, Incyte, Nektar, and Sanofi. Dr Melero has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Incyte, and Roche. He has performed contracted research for or received research support from Pfizer. Dr Aerts has received consulting fees from Bristol-Myers Squibb, AstraZeneca, MSD, Roche, Eli Lilly, and Boehringer Ingelheim. He has performed contracted research or received research support from Eli Lilly and Roche. He has received fees for non-CME services from AstraZeneca. He has ownership interest in Amphera and is in receipt of intellectual property rights or is a patent holder for Amphera dendritic cell immunotherapy. Dr Colombo has no relevant financial relationships to disclose. Dr Coukos has received consulting fees from Genentech, Novartis, Roche, and Sanofi-Aventis. He has received fees for non-CME services from Celgene and Boehringer Ingelheim. Dr Deutsch has received consulting fees from Eisai and Merck. He has performed contracted research or has received research support from AZD, Genentech, Lilly, Roche, and Servier. Dr Powles has received consulting fees from Bristol-Myers Squibb, Eisai, and Merck. He has performed contracted research or received research support from AstraZeneca and Roche. Dr Becker has received consulting fees from Amgen, Bristol-Myers Squibb, CureVac, MerckSerono, Rigontec, and Roche. He has also performed contracted research or received research support from Bristol-Myers Squibb and MerckSerono. Dr Blank has received consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Lilly, MSD, Novartis, Pfizer, and Roche. He has also performed contracted research or has received research support from Novartis. Dr Kiessling has received consulting fees from Bristol-Myers Squibb and Immunicum AB. He has performed contracted research of received research support from Immunicum AB. He is also a board member for CLS AB. Dr Maio has no relevant financial relationships to report. Dr Schuler has received consulting fees from Alexion, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, IQWig, Lilly, Novartis, and Pfizer. He has performed contracted research for or received research support from Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis.

Acknowledgements:

Editorial assistance was provided by Trudy Grenon Stoddert, ELS, of prIME Oncology.

Support:

This educational activity is supported by a grant from Incyte Corporation.

Citation:

EMJ. 2016;1[3]:26-43. DOI/10.33590/emj/10314662. https://doi.org/10.33590/emj/10314662.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.